Abstract Perilla frutescens is an Asian dietary herb consumed as an essential seasoning in Japanese cuisine as well as used for a Chinese medicine. Here, we report that a newly found methoxyflavanone derivative from P. frutescens (Perilla-derived methoxyflavanone, PDMF; 8-hydroxy-5,7-dimethoxyflavanone) shows carcinostatic activity on human lung adenocarcinoma, A549. We found that treatment with PDMF significantly inhibited cell proliferation and decreased viability through induction of G 2 /M cell cycle arrest and apoptosis. The PDMF stimulation induces phosphorylation of tumor suppressor p53 on Ser15, and increases its protein amount in conjunction with up-regulation of downstream cyclin-dependent kinase inhibitor p21
Introduction
Lung cancer is the most common cause of cancer mortality in male and the second cause in female, which is responsible for 1.38 million annual deaths worldwide (Ridge et al. 2013 ). Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. For NSCLC patients with early stages, surgery followed by chemotherapy is the optimal treatment (Sandler et al. 2000) . Although platinum-based doublet chemotherapy is the first-line standard chemotherapy for advanced NSCLC, its response rate is only 30%, resulting in an average of 9 months of overall survival (Azzoli et al. 2009; Socinski 2014) . It is therefore needed to develop safer and more effective therapeutic strategies to treat NSCLC.
Perilla frutescens is an Asian traditional edible plant as well as used for a Chinese medicinal herb. Leaf extract of P. frutescens (PLE) has been reported to possess antioxidant and anti-inflammatory activities (Meng et al. 2009; Yamazaki 1997, 2001) , and ameliorate hepatotoxicity (Kim et al. 2007 ), allergy (Makino et al. 2001 (Makino et al. , 2003 , and obesity ). PLE has also been reported to inhibit growth of human cancer cells (Kwak and Ju 2015; Kwak et al. 2009; Lin et al. 2007) , and suppress skin tumor promotion in mice (Ueda et al. 2003) . Those anti-cancer activities of PLE are reported to be fulfilled by its constituents including luteolin (Ueda et al. 2002 (Ueda et al. , 2003 , rosmarinic acid (Makino et al. 2003; Osakabe et al. 2002; Takano et al. 2004) , and triterpene acids (Banno et al. 2004) .
Our group has recently reported that a new methoxyflavanone derivative from P. frutescens (8-hydroxy-5,7-dimethoxyflavanone, named Perilladerived methoxyflavanone; PDMF) directly suppresses the serine/threonine kinase Akt to inhibit type I hypersensitivity reactions (Kamei et al. 2017) . Akt, also known as protein kinase B (PKB), is a critical regulator of cell proliferation, and its over-activation leads to cancer development (Manning and Cantley 2007) . The targeted action of PDMF to Akt (Kamei et al. 2017 ) prompted us to investigate whether PDMF is also effective for suppression of cancer cell proliferation and survival. In this study, we report a carcinostatic effect of PDMF on human lung adenocarcinoma A549.
Materials and methods

Cell culture and reagents
The A549 human lung adenocarcinoma cell line and WI-38 normal fibroblast (RCB0702) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and RIKEN BRC (Tsukuba, Japan) through the National Bio-Resource Project of the MEXT, Japan, respectively, and were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Tokyo, Japan) containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml penicillin, and 100 lg/ml streptomycin (Life Technologies) in a humidified atmosphere with 5% CO 2 at 37°C. Maintained A549 and WI-38 cells between the 3rd and 10th passages were used for this study. Perilla-derived methoxyflavanone (8-hydroxy-5,7-dimethoxyflavanone; PDMF) was chemically synthesized by Tokyo Chemical Industry (Tokyo, Japan), which had a purity of 99.6% confirmed by high performance liquid chromatography analysis. Doxorubicin was purchased from Sigma-Aldrich. All chemicals used in this study were of analytical or cell-culture grade.
Cell proliferation and viability assays
Cell proliferation was quantified as BrdU incorporation using a colorimetric Cell Proliferation ELISA, BrdU Kit (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. A549 cells were seeded at 5 9 10 3 cells/well and cultured overnight in a 96-well plate. The cells were treated with 3, 7.5, 15, 30, 45, 60 or 75 lg/ml PDMF, or either 580 ng/ml (1 lM) doxorubicin as a positive control or dimethyl sulfoxide (DMSO, vehicle) as a negative control for 24 h. BrdU was added to a final concentration of 10 lM and cultured for the last 2 h. BrdU incorporation was quantified by OD450 according to the manufacturer's instructions.
Trypan blue exclusion assay was used to determine cell viability after treatment with PDMF or doxorubicin. A549 and WI-38 cells (5 9 10 3 cells/well) were cultured in 6-well plates and treated with 30, 45, 60 or 75 lg/ml PDMF, or either 580 ng/ml doxorubicin or DMSO (vehicle) for 24 h. The cultured cells were harvested and re-suspended in 100 ll DMEM, and the cell suspension was thoroughly mixed with an equal volume of 0.4% trypan blue staining solution (Gibco, Grand Island, NY, USA). Numbers of viable and dead cells were counted using a hemocytometer.
Cell cycle and apoptosis analyses
Cell cycle progression or induction of apoptosis of A549 cells was analyzed by a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) using the BD Pharmingen TM FITC-BrdU Flow Kit (BD Biosciences) or the annexin V/propidium iodide (PI) staining kit (BioLegend, San Diego, CA, USA), respectively, according to the manufacturer's instructions. A549 cells were treated with 30, 45, 60 or 75 lg/ ml PDMF, or either 580 ng/ml doxorubicin or DMSO (vehicle) for 24 h. Quantitative analysis of the FACS data was performed with FlowJo software (FlowJo, Ashland, OR, USA).
Western blot analysis A549 cells were harvested, washed twice with chilled PBS, and lysed with ice-cold lysis buffer containing 0.1% sodium lauryl sulfate (SDS), 150 mM NaCl, 1 mM ethylene diamine tetraacetic acid (EDTA), 1% Triton X-100, 2 lg/ml aprotinin, 5 lg/ml Pefabloc SC (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride), a protease inhibitor cocktail (Roche Diagnostics, Tokyo, Japan), 1% phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and 50 mM Tris-HCl (pH 7.4) after 24 h incubation with PDMF, doxorubicin or DMSO (vehicle). The cell lysates were kept on ice for 30 min after gentle vortex, and then were centrifuged at 14,000 g for 15 min at 4°C. The supernatants were either loaded onto SDS-PAGE gel immediately after protein extraction or stored at -80°C until use. The protein concentration was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. For Western blotting, 30 lg protein weight of cell lysate was loaded onto a 15% SDS-PAGE gel under reduced condition. Proteins separated on the gel were transferred onto a PVDF membrane. The PVDF membrane was incubated in blocking buffer containing 3% nonfat milk powder, 1% bovine serum albumin (Sigma-Aldrich) and 0.5% Tween-20 in PBS for 1 h. Subsequently, the PVDF membrane was incubated with anti-p53 polyclonal antibody (pAb), anti-phospho-p53 (pp53) pAb, anti-p21 monoclonal antibody (mAb, clone no. EA10), anti-Akt pAb, anti-pAkt pAb, anti-caspase-3 pAb (Cell Signaling Technology, Beverly, MA, USA), anti-caspase-8 mAb (clone no. 5D3), anti-caspase-9 mAb (clone no. 5B4) (Medical and Biological Laboratories, Nagoya, Japan) or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mAb (clone no. H-12, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight, followed by horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Cell Signaling Technology) or HRP-conjugated anti-mouse IgG (Becton-Dickinson, Durham, NC, USA) for 1 h with agitation at room temperature. Finally, the specific binding to each primary antibody was detected on X-ray film (Konica Minolta Medical Imaging, Wayne, NJ, USA) with ECL prime immunodetection reagent (GE Healthcare, Little Chalfont, UK).
Knockdown of p53 by small interfering RNA (siRNA) transfection Cultured A549 cells (2 9 10 5 cells/well) in a 6-well plate were transfected with 75 pmol p53 siRNA (#106141, Ambion, Austin, TX, USA) or control siRNA (#AM4611, Ambion) with Lipofectamine 2000 (Invitrogen). The selectivity of the siRNA was validated and confirmed by its supplier. After 48 h incubation, 1.5 ml fresh DMEM medium was added and then cultured with 75 lg/ml PDMF, 580 ng/ml doxorubicin, or DMSO (vehicle) for an additional 24 h.
Statistical analysis
Data are represented as mean ± SD. Non-repeated ANOVA with post hoc Dunnett's test was performed to determine the statistical significance compared to a corresponding negative control. Statistical significance was defined as P \ 0.05. The IC 50 of PDMF for A549 and WI-38 cell viability was calculated using Graph Pad Prism 5 (Version 5.01, GraphPad Software, San Diego, CA, USA). The data shown in the figures are representative data for three independent experimental results.
Results
Stimulation with PDMF impairs cell proliferation and decreases viability in A549 human lung adenocarcinoma
We first analyzed whether stimulation with PDMF affect cell proliferation and viability in A549 cells. BrdU incorporation assay revealed that treatment with PDMF (30-75 lg/ml) significantly inhibited cell proliferation in a dose-dependent manner (Fig. 1a) . We also found that stimulation with 45-75 lg/ml of PDMF showed cytotoxicity on A549 cells (Fig. 1b) .
PDMF induces G 2 /M cell cycle arrest in A549 cells
We next investigated the effect of PDMF on cell cycle progression of A549 cells. Flow cytometric analysis of anti-BrdU-FITC-and 7-AAD-stained A549 cells indicated that treatment with PDMF (45-75 lg/ml) triggered cell cycle arrest at G 2 /M phase in a dosedependent manner, while cell numbers at the G 1 and S phases showed a slightly but statistically significant decrease as compared with those in the vehicle as a negative control (Fig. 2a, b) . The potency of PDMFdriven G 2 /M phase cell cycle arrest was comparable to that seen in doxorubicin (580 ng/ml)-treated A549 cells as a positive control. These results suggest that the PDMF-driven anti-proliferative activity is attributable to the induction of G 2 /M cell cycle arrest in A549 cells.
Proapoptotic potency of PDMF
To examine whether PDMF-induced cell death in A549 cells was associated with apoptosis, PDMFtreated A549 cells were analyzed by flow cytometry using a combination of annexin V and propidium iodide (PI) staining. We found that treatment with PDMF (45-75 lg/ml) resulted in a significant accumulation of early (Annexin V ? PI -) and late (Annexin V ? PI ? ) apoptotic cells (Fig. 3a) , and that total annexin V-positive apoptotic cells significantly increased in a dose-dependent manner (Fig. 3b ). These data clearly show proapoptotic potency of PDMF on A549 cells.
PDMF stimulation induces phosphorylation of p53 and increases its protein amount
To elucidate the molecular mechanism by which PDMF fulfilled carcinostatic activity on A549 cells, we first examined the effect of PDMF on the expression and activation of tumor suppressor p53, since A549 cells carried wild-type p53 alleles (Lehman et al. 1991) . We found that stimulation with PDMF (45-75 lg/ml) induced serine phosphorylation of p53 (pp53) on Ser15 (Fig. 4a, b) , a critical posttranslational modification of p53 by its upstream kinases ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related kinase (ATR) upon DNA damage checkpoint responses (Siliciano et al. 1997; Tibbetts et al. 1999) . We also found that PDMF significantly increased the protein amount of p53 in a dose-dependent manner (Fig. 4a, c) . These results suggest that stimulation with PDMF up-regulates p53 through its activation and protein induction. Consistent with the up-modulation of p53, we found that PDMF stimulation induced protein levels of p21 Cip1/Waf1 (Fig. 4a, d ), a p53-responsive cyclindependent kinase (CDK) inhibitor (El-Deiry et al. 1993) .
We next sought to see a possible mechanism by which PDMF increased p53 protein levels in A549 cells (Fig. 4a) . It has been well-known that Akt enhances MDM2-mediated degradation of p53 (Ogawara et al. 2002) , and our group has recently demonstrated that PDMF directly acts on Akt to suppress its phosphorylation (Kamei et al. 2017) . These results raise a possibility that PDMF could induce p53 protein levels via its direct inhibition of Akt, which negatively regulates the MDM2-driven p53 degradation pathway in A549 cells. Indeed, we confirmed that stimulation with PDMF significantly suppressed phosphorylation of Akt on serine 473 (Ser473) in a dose-dependent manner (Fig. 4e, f) . These results indicate that PDMF activates p53 and increases its protein amount, both of which could be involved in its carcinostatic effect on A549 cells.
PDMF activates proapoptotic caspases
Proapoptotic action of p53 is fulfilled by downstream caspases: caspase-9 and caspase-3 (Schuler et al. 2000) . We next tested whether PDMF activates those caspases to fulfill its proapoptotic potency. Western blot analysis revealed that stimulation with PDMF triggered cleavage of caspase-9 and caspase-3 in comparison to the vehicle as a negative control (Fig. 5a, b , and c). We also found that PDMF induced cleavage of caspase-8 (Fig. 5a, d ), another proapoptotic caspase involved in the death receptor-mediated induction of apoptosis upon cross-linking with TNF family member ligands (Elmore 2007) . These results suggest that PDMF activates proapoptotic caspase cascades downstream of p53 and cell surface death receptors.
p53 is essential for PDMF-induced G 2 /M cell cycle arrest and apoptosis in A549 cells To test whether p53 was needed for PDMF-driven G 2 / M cell cycle arrest and apoptosis, we knocked down p53 expression in A549 cells by siRNA transfection.
We first confirmed that p53 protein expression was successfully suppressed upon transfection with p53 siRNA, but not with negative control siRNA (Fig. 6a,  b) . We also found that stimulation with PDMF or doxorubicin (a positive control anticancer agent for p53-driven cell cycle arrest and apoptosis) normally induced p53 protein expression in control A549 cells transfected with negative siRNA and sham-treated with no siRNA (Fig. 6c, d ), while transfection with p53 siRNA fully abrogated induction of p53 protein upon stimulation with PDMF or doxorubicin (Fig. 6c,  d ). These results clearly indicate that our p53 knockdown experiment is successfully done with siRNA transfection, and that those experimental settings would offer an appropriate in vitro system to evaluate possible involvement of p53 in the carcinostatic effect of PDMF.
We next analyzed the impact of p53 knockdown on the G 2 /M cell cycle arrest of A549 cells upon stimulation with PDMF. As shown in Fig. 7a and b, transfection with p53 siRNA completely abolished the G 2 /M cell cycle arrest induced by PDMF. We also examined the effect of p53 knockdown on apoptosis induction of A549 cells upon stimulation with PDMF. Transfection with p53 siRNA substantially decreased the annexin V-positive apoptotic cells induced by PDMF (Fig. 7c, d ), but the proapoptotic action of PDMF was not fully abrogated upon knockdown of p53. These results suggest that p53 is required for the induction of PDMF-driven G 2 /M cell cycle arrest in A549 cells, while the proapoptotic potency of PDMF was fulfilled in p53-dependent and -independent manners.
Discussion
Chinese herbal medicines exhibit effective anti-tumor activities with minimal toxicity and are a valuable source of novel chemotherapeutic agents (Li et al. 2015) . P. frutescens is an active medicinal plant with various pharmacological effects on antitumor activity. Our group has recently discovered a new P. frutescens-derived methoxyflavanone derivative (8-hydroxy-5,7-dimethoxyflavanone), named Perilladerived methoxyflavanone (PDMF), that directly suppresses Akt to inhibit type I hypersensitivity reactions (Kamei et al. 2017) . Since Akt is a critical b Fig. 3 Proapoptotic potency of PDMF on A549 cells. were quantified upon normalization with that of GAPDH.
e PDMF suppresses Akt phosphorylation. Protein levels of pAkt (on Ser473) and Akt were detected by western blot analysis. f The relative protein expression levels of pAkt (Ser473) normalized with those of total Akt were quantified by the Image J software. The values are the mean ± SD of three different experiments. * P \ 0.05 indicates significant differences compared with vehicle may also have anti-tumor potential less than or comparable to PDMF (IC 50 : 27-238 lg/ml in hepatoma and breast cancer cell lines) (Arul and Subramanian 2013; Ayob et al. 2014 ). These evidences implicate that PDMF represents an additional flavanone derivative whose anti-tumor potency is superior or comparable to other known flavanones.
PDMF preferentially induced G 2 /M cell cycle arrest and a slight increase in sub-G 1 cells. Corresponding to the significant increase in G 2 /M cells, population of cells at S phase was significantly and dominantly decreased upon treatment with more than 60 lg/ml PDMF compared with vehicle control (Fig. 2b) . The cell cycle distribution of PDMF-treated A549 cells was similar to that of doxorubicin-treated cells (Fig. 2) . These data imply a similar anti-proliferative action between PDMF and doxorubicin.
We showed that PDMF significantly inhibited tumor cell growth through induction of G 2 /M cell cycle arrest and apoptosis in A549 cells in a p53-dependent manner (Figs. 2, 3, 7) . p53 plays a key role in cell cycle regulation and apoptosis. Activated p53 induces G 1 and/or G 2 /M cell cycle arrest by activating its target genes, or by its direct negative regulation of corresponding cyclins and CDKs (Agarwal et al. 1998; Flatt et al. 2000) . Although our data clearly show the PDMF-driven carcinostatic effects on A549 cells are mainly fulfilled by p53, detailed molecular mechanism underlying the p53-driven G 2 /M cell cycle arrest is largely unknown. Especially, involvement of p21 Cip1/Waf1 on the G 2 /M arrest needs to be clarified in future studies. In addition, further analysis is needed to elucidate upstream molecular events by which PDMF activates p53. Such candidate molecules are ATM and ATR, that up-modulate p53 through phosphorylation on Ser15. Since ATM and ATR work as DNA damage sensors upstream of p53 (Siliciano et al. 1997; Tibbetts et al. 1999) , to test whether PDMF induces DNA damage to activate p53 pathway is another important issue to be addressed.
We also have analyzed carcinostatic effect of PDMF on four human leukemia cell lines (CCRF- CEM, Jurkat, KG1a, and K-562 cells), but no effect is seen against these cells whose p53 is inactivated or deficient (data not shown). One possibility for this non-effectiveness is that the efficacy of PDMF is dependent on p53 status in cancer cells, since p53 is indeed essential for the anti-tumor effect of PDMF (Fig. 7) . Further analysis on other human cancer cells is needed to confirm this possibility.
Induction of apoptosis is also important for the effective therapeutic strategy for cancer treatment (Riedl and Salvesen 2007; Ma et al. 2013; Srinivasan et al. 2009 ). Two convergent cascades have been reported to induce apoptosis: extrinsic pathway is executed by death receptor-initiated proapoptotic signals transduced via Fas/Fas ligand system and TNF family cytokines (Ashkenazi and Dixit 1999; Hengartner 2000) , and the other intrinsic pathway is activated by genotoxic stresses leading to activation of caspase-9 (Hengartner 2000) . Gain-of-function of p53 can activate both pathways, and cause apoptosis via caspase-3 activation Amaral et al. 2010) . A signaling pathway which links those two proapoptotic signaling events was also known as a cross-talk pathway (Chen et al. 2009; Cohen 1997) . The PDMF-induced apoptosis in A549 cells is accompanied by activation of caspases-3, 8 and 9 in a dose-dependent manner (Fig. 5) , suggesting that the PDMF-driven apoptotic action is fulfilled by both extrinsic and intrinsic signaling pathways. Our result that partial abrogation of the PDMF-induced apoptosis by knockdown of p53 (Fig. 7c, d ) supports the idea that PDMF can also induce apoptosis via p53-independent proapoptotic pathways such as the death receptor-driven mechanisms.
PDMF induces G 2 /M cell cycle arrest and apoptosis in A549 cells in dose more than 45 lg/ml (IC 50 : 53.5 lg/ml, Fig. 1a, b) . Although the dosages seem to be a little bit high for pharmaceutical use of chemotherapy to NSCLC, and could be decreased by use of chemical derivatives from PDMF. Another possible application of PDMF for cancer chemoprevention is to be used for prevention of NSCLC by oral intake of PDMF per se or PDMF-enriched P. frutescens extract. To further gain insight into the therapeutic and preventive effects by PDMF, additional in vivo experiments are needed to analyze the anti-tumor potency of PDMF and PDMF-derivatives. We are also trying to test the efficacy of low dose PDMF upon co-administration with established anticancer drugs. PDMF shows less cytotoxicity to human normal cells (WI-38 lung fibroblast) than to A549 cells (IC 50 for WI-38: [75 lg/ml, data not shown), while this observation still warrants its possible side effect on normal cells. Thus, a decrease in PDMF dosage would be preferable for its ideal application to cancer prevention. Our preliminary study indicates that a combination treatment with low dose PDMF and anticancer tyrosine kinase inhibitors shows a synergistic tumor suppressive effect in vitro as well as in vivo (Abd El-Hafeez A.A., Fujimura T., and Kawamoto S., unpublished data). Further investigation is needed for the development of cancer preventive strategies using PDMF.
In summary, here we found that PDMF, a methoxyflavanone derivative from P. frutescens, showed a carcinostatic effect on A549 human lung adenocarcinoma through its action to tumor suppressor p53. Strikingly, the PDMF-driven G 2 /M cell cycle arrest and its proapoptotic potency is dependent on p53, suggesting that PDMF would be useful for prevention of carcinogenesis and/or elimination of pre-cancer lesions carrying wild type p53 alleles. These findings provide a new insight into the cancer chemoprevention by edible plant phytochemicals.
